Interviews

A groundbreaking clinical trial explores botensilimab/balstilimab combination therapy, offering new hope for advanced colorectal cancer patients lacking effective immunotherapy options.

Researchers identify IL-6 as a key biomarker predicting resistance to CDK4/6 inhibitors in metastatic breast cancer, highlighting new therapeutic targets.

Experts explore the potential of invasive disease-free survival as a key metric in breast cancer trials, aiming to accelerate treatment approvals.

Christina Poh, MD, explores tafasitamab's universal benefits for follicular lymphoma treatment, highlighting its practical adoption and safety for all patients.

George Mulligan, PhD, highlights the importance of clinical trials and innovative research in advancing myeloma treatment and pursuing potential cures.

New research unveils a promising monoclonal antibody therapy targeting CALR mutations in essential thrombocythemia, aiming to improve patient outcomes.

Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

George Mulligan, PhD, explores the impact of linvoseltamab's FDA approval on multiple myeloma treatment, highlighting innovative bispecific antibodies and patient-centered strategies.

Research advances in blood cancer treatment enhance donor matching and reduce graft-vs-host disease, improving access to life-saving transplants for diverse patients.

Dr Patrick Wen discusses the FDA approval of dordaviprone, highlighting its potential to improve outcomes for patients with challenging brain tumors.

Researchers explore TAF1's role in leukemia, revealing potential targeted therapies that could transform treatment approaches for acute myeloid leukemia.

Study reveals alarming treatment gaps in high-risk Myelodysplastic Syndromes, highlighting disparities and adherence issues that impact patient outcomes.

A recent study uncovers disparities in treatment patterns for myelodysplastic syndromes, revealing critical insights into patient outcomes and care access.

Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict patient outcomes.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of Chief Insights in Oncology.

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating CAR T toxicities.

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving the way for targeted therapies.

Experts explore advancements in bronchoscopic biopsies for lung cancer, emphasizing safety, sample adequacy, and the importance of rapid biomarker testing.

A clinical study reveals talquetamab's effectiveness as a bridging therapy before CAR T-cell treatment for multiple myeloma, enhancing patient outcomes.

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.

Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.

IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple myeloma research.

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high efficacy and safety.

Fertility preservation becomes crucial for reproductive-age cancer patients, emphasizing timely intervention and collaboration between oncology and reproductive specialists.

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.